Project Grant HT94252510063
Award Date
4/1/25
Completion Date
3/31/28
Dollars Obligated
$2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
This $507,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting research at the Icahn School of Medicine at Mount Sinai (ISMMS) to study the role of exosomes in promoting prostate cancer metastasis and resistance to androgen deprivation therapy. The 2-year grant, awarded on June 15, 2024, will enable ISMMS to conduct innovative biomedical research with the goal of advancing understanding and treatment of...
The Icahn School of Medicine at Mount Sinai will receive $1,420,835 under a three-year Project Grant from the Defense Health Agency to target the immunosuppressive microenvironment of prostate cancer and enhance the therapeutic efficacy of immune checkpoint inhibitors.
The grant, awarded June 1, 2023 under the Military Medical Research and Development program (CFDA 12.420), will support basic, applied, and advanced biomedical research aimed at transforming health care for service members and...
The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
The Defense Health Agency has awarded a $766,079 Project Grant to the Icahn School of Medicine at Mount Sinai to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from September 1, 2023 to August 31, 2026, aims to "UNRAVEL THE EVOLUTION OF MELANOMA WITHIN THE HOST IMMUNE ECOSYSTEM." As a leading private medical research institution, the Icahn School of Medicine at Mount Sinai has a history of providing a wide range of...
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,561,500.00 to Health Research, Inc. at Roswell Park Cancer Center to conduct research targeting prostate cancer metabolic vulnerabilities in the bone microenvironment. The goal is to develop new approaches to circumvent lethal metastatic disease. The 3-year award period runs from September 15, 2023 to September 14, 2026. As a non-profit research...
The U.S. Defense Health Agency awarded a $1,522,278 Project Grant to Weill Medical College of Cornell University on September 30, 2024 under the Military Medical Research and Development program (CFDA 12.420). The grant supports a research project titled "Decoding Bone Metastasis in Prostate Cancer: A Multimodal Approach Integrating Genomics and Imaging Data." The project aims to advance scientific understanding and improve treatment of bone metastasis in prostate cancer patients...
This federal Project Grant award of $202,800.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the Icahn School of Medicine at Mount Sinai (ISMMS) to investigate "Spatial Copy Number and Morphologic Alterations in Early Lung Carcinogenesis." The award period runs from September 30, 2025 to September 29, 2026. ISMMS, a renowned academic medical center and research institution in New York City, will...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is providing $1,014,000.00 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at creating cures for patients with Langerhans cell histiocytosis. The research, which is scheduled to take place from September 1, 2024 to August 31, 2028, will leverage the institution's expertise in areas such as cancer biology, immunology, and clinical...
The Department of Defense's Defense Health Agency awarded a $1,460,695 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. for the project "Development and Validation of an Epigenomic Landscape and Novel Immunotherapy in Prostate Cancer Disparities". The award period is from September 1, 2025 to August 31, 2028. The purpose of this grant is to support research...
The Defense Health Agency awarded a $1,561,500 Project Grant to Health Research, Inc. Roswell Park Division for the period of March 15, 2023 through March 14, 2026. The grant will support research into slow-cycling prostate cancer cells in therapy resistance, disease relapse, and metastasis.
This award is being made under the Military Medical Research and Development program (CFDA 12.420). This program aims to transform military and public health through innovative medical research solutions...